A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062672 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Pei Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, China Pharmaceutical University, 639 Long Mian Avenue, Nanjing 211198, China. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Blood Glucose, Body Weight, Recombinant Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Funding Program for Excellent Postdoctoral Talent, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Fibroblast growth factor 21 (FGF21), a hormone-like protein, plays a crucial role in enhancing glucose and lipid metabolism, offering promising therapeutic avenues for conditions such as nonalcoholic steatohepatitis and severe hypertriglyceridemia. Despite its potential, this protein’s limited stability and brief half-life pose significant challenges for its use in clinical settings. In this study, we created an FGF21 analog (named FGF21-164) that is a mutant of FGF21 and fused it with the tandem repeat sequence of human CD164. FGF21-164, characterized by extensive glycosylation and sialylation, exhibits enhanced pharmacokinetic properties, particularly in terms of its significantly longer half-life compared to its native form. The in vitro efficacy of FGF21-164 was evaluated using 3T3-L1-induced adipocytes. The protein demonstrated a dose-dependent increase in glucose uptake and effectively decreased lipid droplet accumulation surrounding the adipocytes. The in vivo activity of FGF21-164 was evaluated in leptin-deficient (ob/ob) and diet-induced obesity (DIO) mice. A single subcutaneous dose of FGF21-164 led to a rapid decrease in blood glucose levels and sustained normal fasting glucose levels for up to 28 days. Additionally, repeated dosing of FGF21-164 significantly curbed weight gain and reduced hepatic fat accumulation in DIO mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, China Pharmaceutical University, 639 Long Mian Avenue, Nanjing 211198, China.
- Glycomics and Glycan Bioengineering Research Center (GGBRC), College of Food Science and Technology, Nanjing Agricultural University, 1 Weigang, Nanjing 210095, China.
Förderung
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Du, P., Wang, T., Wang, R., Liu, S., Wang, H., & Yin, H. (2025). A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062672
Vancouver
Du P, Wang T, Wang R, Liu S, Wang H, Yin H. A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062672
BibTeX
@article{Du2025,
author = {Du, Pei and Wang, Ting and Wang, Rong and Liu, Shang and Wang, Hang and Yin, Hongping},
title = {A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062672}
}
EUVIMED